Use of pro-atrial natriuretic peptide in the detection of myocardial ischaemia

被引:3
|
作者
Bocek, T
Morgenthaler, NG
Staub, D
Nusbaumer, C
Christ, A
Zellweger, MJ
Mueller-Brand, J
Mueller, B
Perruchoud, AP
Mueller, C
机构
[1] Univ Basel Hosp, Med Klin A, Dept Internal Med, Med Div A, CH-4031 Basel, Switzerland
[2] Brahms AG, Berlin, Germany
[3] Univ Basel Hosp, Dept Lab Med, CH-4031 Basel, Switzerland
[4] Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland
[5] Univ Basel Hosp, Div Nucl Med, CH-4031 Basel, Switzerland
[6] Univ Basel Hosp, Clin Endocrinol Diabet & Clin Nutr, CH-4031 Basel, Switzerland
关键词
exercise; ischaemia; natriuretic peptides;
D O I
10.1111/j.1365-2362.2005.01517.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Because of its unique storage and release mechanisms allowing a very rapid response to haemodynamic changes, pro-atrial natriuretic peptide (proANP) may be a helpful cardiac marker in the detection of myocardial ischaemia. Materials and methods A total of 260 consecutive patients with suspected myocardial ischaemia referred for rest/ergometry myocardial perfusion single-photon emission computed tomography (SPECT) were enrolled. Levels of plasma proANP were determined before and 1 min after maximal exercise. Results Baseline proANP and peak exercise proANP were significantly higher in patients with myocardial ischaemia as compared to those without ischaemia (median, 82 [IQR, 57-112] vs. 67 [IQR, 50-106] pmol L-1, P = 0.007; and 89 [IQR, 65-121] vs. 78 [IQR, 57-116] pmol L-1, P = 0.033). The area under the ROC curve for baseline proANP was 0.597 (95% CI, 0.527-0.667), as compared to 0.577 (95% CI, 0.507-0.648) for peak exercise proANP. Exercise-induced changes in proANP were similar in patients with and without myocardial ischaemia, and showed no correlation with the extent of myocardial ischaemia. Conclusions Baseline proANP and peak exercise proANP are significantly higher in patients with myocardial ischaemia. However, because of considerable overlap in proANP levels between patients with and without myocardial ischaemia, neither measurement seems helpful in the detection of myocardial ischaemia in clinical practice.
引用
收藏
页码:450 / 456
页数:7
相关论文
共 50 条
  • [1] Impact of pro-atrial natriuretic peptide in atrial fibrillation and stroke
    Roever, Leonardo
    Resende, Elmiro Santos
    Roerver-Borges, Anaisa Silva
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (12) : 1239 - 1241
  • [2] Midregional pro-atrial natriuretic peptide in the general population
    Tzikas, Stergios
    Keller, Till
    Wild, Philipp S.
    Schulz, Andreas
    Zwiener, Isabella
    Zeller, Tanja
    Schnabel, Renate B.
    Sinning, Christoph
    Lubos, Edith
    Kunde, Jan
    Muenzel, Thomas
    Lackner, Karl J.
    Blankenberg, Stefan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (05) : 1125 - 1133
  • [3] Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia
    Prat, Cristina
    Lacoma, Alicia
    Dominguez, Josep
    Papassotiriou, Jana
    Morgenthaler, Nils G.
    Andreo, Felipe
    Tudela, Pere
    Ruiz-Manzano, Juan
    Ausina, Vicente
    JOURNAL OF INFECTION, 2007, 55 (05) : 400 - 407
  • [4] Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans
    Zois, Nora E.
    Terzic, Dijana
    Faerch, Kristine
    Plomgaard, Peter
    Hansen, Jakob S.
    Rossing, Peter
    Goetze, Jens P.
    EBIOMEDICINE, 2017, 17 : 88 - 94
  • [5] Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes
    Wu, F
    Yan, W
    Pan, JL
    Morser, J
    Wu, QY
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) : 16900 - 16905
  • [6] Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy
    Elif Elmas
    Christina Doesch
    Stephan Fluechter
    Miriam Freundt
    Christel Weiss
    Siegfried Lang
    Thorsten Kälsch
    Dariush Haghi
    Jana Papassotiriou
    Jan Kunde
    Stefan O. Schoenberg
    Martin Borggrefe
    Theano Papavassiliu
    The International Journal of Cardiovascular Imaging, 2011, 27 : 547 - 556
  • [7] N-terminal pro-atrial natriuretic peptide and exercise prescription in patients with myocardial infarction
    Ikeda, Nahoko
    Yasu, Takanori
    Nishikimi, Toshio
    Nakamura, Tomohiro
    Kubo, Norifumi
    Kawakami, Masanobu
    Momomura, Shin-ichi
    Saito, Muneyasu
    REGULATORY PEPTIDES, 2007, 141 (1-3) : 154 - 158
  • [8] Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy
    Elmas, Elif
    Doesch, Christina
    Fluechter, Stephan
    Freundt, Miriam
    Weiss, Christel
    Lang, Siegfried
    Kaelsch, Thorsten
    Haghi, Dariush
    Papassotiriou, Jana
    Kunde, Jan
    Schoenberg, Stefan O.
    Borggrefe, Martin
    Papavassiliu, Theano
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2011, 27 (04): : 547 - 556
  • [9] Immunoluminometric assay for the midregion of pro-Atrial natriuretic peptide in human plasma
    Morgenthaler, NG
    Struck, J
    Thomas, B
    Bergmann, A
    CLINICAL CHEMISTRY, 2004, 50 (01) : 234 - 236
  • [10] Use of B-type natriuretic peptide in the detection of myocardial ischaemia
    Mueller, C.
    Staub, D.
    Zellweger, M.
    Jonas, N.
    Pfisterer, M.
    Perruchoud, A.
    EUROPEAN HEART JOURNAL, 2005, 26 : 41 - 41